论文信息 - Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update - 字舞流文

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

A. Jakubowiak | J. Laubach | P. Richardson | R. Orlowski | P. Voorhees | J. Kaufman | Y. Efebera | D. Sborov | A. Chari | J. Vermeulen | K. Shain | A. Cowan | C. Costello | J. Ukropec | T. Wildes | L. Costa | N. Shah | R. Silbermann | H. Pei | B. Reeves | C. Rodriguez | N. Nathwani | D. Hoehn | L. Anderson | T. Lin | C. Boer | Y. Lutska | S. Murphy